Transgene Biotek has inked pact with Atral Cipan of Portugal by signing Tacrolimus Licensing and Technology Transfer agreement. As per the agreement, Atral Cipan will move the products through regular filings with the USFDA and European Medicines Agency (EMEA) for manufacturing and marketing Tacrolimus.
Both companies believe that Transgene’s experience and skills in developing technologies, coupled with the global presence and pharmaceutical experience of Atral Cipan, will expand the commercialization and marketing of Tacrolimus across several developed markets including the US and Europe.
